´óÐãÊÓƵ

Public policy has the potential to enable the development of the next generation of medical advances and unlock the power of health. ´óÐãÊÓƵ's role in these discussions is to work to ensure that policy positively impacts the people who rely on our work, our employees and our ability to continue to develop new products. At the federal and state levels, we engage with governments, think tanks, trade associations, patient groups and other organizations to find policy solutions to the complex issues that challenge our healthcare system. It is our responsibility to help policymakers understand ´óÐãÊÓƵ's viewpoints on major healthcare issues.

´óÐãÊÓƵ's public policy engagement is guided by the following principles:

• ´óÐãÊÓƵ is committed to ethical behavior and transparency and is guided by our Code of Business Conduct in all our activities, including public policy engagement. ´óÐãÊÓƵ's public policy activities comply with all applicable laws and regulations and adhere to ´óÐãÊÓƵ policies. ´óÐãÊÓƵ, relevant ´óÐãÊÓƵ employees, and external lobbyists and firms register as lobbyists and file lobbying and contribution disclosures as required by applicable law.
• The Government Affairs function has the primary responsibility for public policy engagement in the U.S. under the direction of the Vice President of Government Affairs. The Public Policy Committee of the Board of Directors reviews an annual report of ´óÐãÊÓƵ's public policy activities, including advocacy priorities, political contributions, lobbying activities, and trade association memberships and dues.
• ´óÐãÊÓƵ pursues activities to shape policies that impact the Company and benefit the people who need our products, with a focus on improving access to new medical advances, and helping people live fuller, healthier lives.

´óÐãÊÓƵ's Government Affairs function, under the direction of the Vice President, Government Affairs, is responsible for our U.S. advocacy activities, including managing all direct advocacy at the federal, state, and local levels, and managing ´óÐãÊÓƵ's relationships with trade associations and similar groups with respect to their advocacy efforts. Our Federal Government Affairs office in Washington, D.C. is responsible for advocacy activities with the U.S. Congress and the federal government. Advocacy at the U.S. state level is managed by our State Government Affairs function. ´óÐãÊÓƵ also hires outside firms that can provide expertise on our key policy issues. ´óÐãÊÓƵ does not currently make direct expenditures towards U.S. federal or state grassroots lobbying communications to the general public. Were ´óÐãÊÓƵ to engage in this area, such activity would be managed by the Vice President of Government Affairs.

The Public Policy Committee of the ´óÐãÊÓƵ Board of Directors is responsible for oversight of ´óÐãÊÓƵ's Government Affairs function and public policy issues that affect or could affect ´óÐãÊÓƵ's business, performance, and public image, as well as reviewing and evaluating ´óÐãÊÓƵ's governmental affairs and political participation, including advocacy priorities, political contributions, lobbying activities, and trade association memberships. The Public Policy Committee also has responsibility for evaluating ´óÐãÊÓƵ's sustainability and social responsibility practices and reviewing social, political, economic, and environmental trends. For additional information regarding ´óÐãÊÓƵ's Public Policy Committee, please refer to the Committee's charter.

´óÐãÊÓƵ is committed to enabling people to live fuller, healthier lives through better health and we strive to make an impact on policies and priorities that have a positive effect on people's health and well-being, including enabling broader accessibility to and affordability of medical innovation. In furtherance of this commitment, ´óÐãÊÓƵ engages in advocacy with respect to public policy developments that may have a significant impact on this objective and on its business. ´óÐãÊÓƵ regularly engages in advocacy on the following issues: promoting access to medical innovation; promoting competitive tax policy that enhances innovation; global trade issues; strengthening our supply chain; and promoting sustainability and responsible stewardship of our resources.

´óÐãÊÓƵ files quarterly reports, in compliance with the Lobbying Disclosure Act, that include: 1) total federal lobbying expenditures, 2) the name of the specific piece of legislation or subject that was the topic of communication, 3) disclosure of ´óÐãÊÓƵ individuals who lobbied on behalf of ´óÐãÊÓƵ and 4) identification of the legislative body or executive branch that was contacted. The quarterly reports provide additional detail on active lobbying priorities and incorporate expenses associated with lobbying the federal government, including our Federal Government Affairs office and the portion of trade association dues associated with federal lobbying. In 2023, ´óÐãÊÓƵ reported $3,890,000 in U.S. federal lobbying. ´óÐãÊÓƵ's latest Federal lobbying disclosure filings can be found on the Ìýor theÌýÌý The Public Policy Committee of the ´óÐãÊÓƵ Board of Directors reviews an annual report of our advocacy priorities.

Download ´óÐãÊÓƵ's most recent LD-2 here. Please see below to download previous quarters' reports of ´óÐãÊÓƵ's LD-2.

´óÐãÊÓƵ participates in the political process by contributing to U.S. state and local candidates and political organizations. We support candidates and organizations that understand how government actions can affect access to medical advances, and that will work to promote an environment that fosters continued medical progress. We have not made direct independent expenditures on behalf of candidates running for public office and do not have plans to make independent expenditures. If such expenditures are made, they will be included in our semi-annual report.

Contributions to office holders and candidates are bipartisan, made without regard for the private political preferences of our officers and executives, and based on several criteria: 1) a philosophy that reflects ´óÐãÊÓƵ's commitment to supporting access to medical innovation and improving lives through good health, 2) key legislative committee and/or leadership assignments, 3) represents an ´óÐãÊÓƵ facility or a significant number of ´óÐãÊÓƵ employees, 4) electability and need for financial support.

´óÐãÊÓƵ's Government Affairs function, under the direction of the Vice President, Government Affairs, reviews and approves all corporate political contributions to ensure these contributions are consistent with the company's guidelines and in accordance with applicable laws. The Public Policy Committee of the ´óÐãÊÓƵ Board of Directors annually reviews the company's U.S. political contributions policy and a report of the company's U.S. political contributions.

Download the 2024 Corporate Political Contributions report for January 1 - December 31, 2024 here. Please see below to download previous years' reports of ´óÐãÊÓƵ's corporate contributions to political candidates, political parties, political committees, ballot measure committees and organizations operating under 26 USC Sec. 527 of the Internal Revenue Code.